Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 04, 2015 8:35 PM ET

Life Sciences Tools and Services

Company Overview of SeraCare Life Sciences, Inc.

Company Overview

SeraCare Life Sciences, Inc. provides products and services to facilitate the discovery, development, and production of human and animal diagnostics, and therapeutics. The company’s Diagnostic and Biopharmaceutical Products segment offers controls and panels for the evaluation and quality control of infectious disease tests in clinical laboratories, blood banks, and in vitro diagnostic (IVD) manufacturing; and reagents and bioprocessing products for use in the discovery, development and manufacturing processes for drugs, vaccines, and diagnostic tests. It also provides diagnostic intermediates for use in manufacturing diagnostic test kits; cell culture additives and media that maintain viabi...

37 Birch Street

Milford, MA 01757

United States

Founded in 1984

193 Employees





Key Executives for SeraCare Life Sciences, Inc.

Chief Executive Officer and President
Chief Financial Officer and Secretary
Age: 67
Vice President of Human Resources
Age: 58
Vice President of Manufacturing Operations
Age: 60
Compensation as of Fiscal Year 2015.

SeraCare Life Sciences, Inc. Key Developments

SeraCare Life Sciences Announces Launch of NGS Validated HIV-1 Reference Materials

SeraCare Life Sciences announced that the company's new precision medicine business unit has launched Seraseq™ HIV-1 Reference Materials; a portfolio consisting of 12 individual high-titer HIV-1 viral isolates that have been characterized by next-generation sequencing (NGS). These products are intended for use with targeted NGS assays that determine HIV-1 subtype, identify drug resistance mutations or assign viral tropism. HIV drug resistance has tremendous consequences in terms of treatment failure and overall health care costs. With increasing numbers of drug resistance mutations being characterized, Sanger sequencing-based assays have been the preferred genotyping method. However, it has been recognized that they are limited in their ability to detect critical minority variants below 20% frequency. As clinical laboratories access to NGS technology increases, so will the ability to develop assays with improved sensitivity. Reference materials with clinically actionable resistance mutations that have been characterized by NGS-methods are critical for labs developing NGS-based assays for HIV. Seraseq™ HIV-1 Reference Materials are high-titer isolates that can be used to validate new assays, compare different test results as well as monitor assay performance on an ongoing basis.

SeraCare Life Sciences, Inc. Signs Partnership Agreement with ViveBio, LLC

SeraCare Life Sciences, Inc. signed a partnership agreement with ViveBio, LLC to enable next generation preanalytic products for the in vitro diagnostics (IVD) industry. Both the entities are based in the US. Under the terms of the agreement, SeraCare and ViveBio will jointly market and sell their combined technologies into the in vitro diagnostic development market.

Seracare Life Sciences Launches Seraseq™ Solid Tumor Mutation Mix—I (AF20)

SeraCare Life Sciences announced that the company's new precision medicine business unit has launched its first product, the Seraseq™ Solid Tumor Mutation Mix—I (AF20); a biosynthetic reference material designed to evaluate the performance of next generation sequencing (NGS)-based tumor profiling assays. This product contains a mixture of mutations in key oncogenes and tumor suppressor genes and is intended as a quality material for translational and disease research testing. In addition, it permits laboratories to monitor library preparation, sequencing and variant allele detection under a given set of bioinformatics pipeline or parameters. It is currently for research use only. Clinical laboratories that have adopted next-generation sequencing for somatic mutation detection typically maintain their own pre-diluted mixtures of characterized cell-line DNA, which is labor intensive, inconsistently characterized and of unknown stability and variability. A well-designed quality control program is critical for providing reliable results obtained for unknown specimens. The use of independent reference products may provide valuable information concerning assay sensitivity and bioinformatics pipeline analysis. Seraseq™ Solid Tumor Mutation Mix is a mixture of biosynthetic target genes with specific engineered mutations in a wild-type background of well-characterized genomic DNA, and is compatible with all major cancer hotspot oncology panels and NGS platforms on the market. With a novel internal quality marker, Seraseq™ Solid Tumor Mutation Mix makes it simple to analyze and monitor potential laboratory contamination levels over time. This first version includes 26 major cancer 'hotspot' genes, all at 20% allelic frequency and quantitated using digital PCR to ensure high accuracy. It is stable for two years under recommended storage conditions, and can undergo ten freeze-thaw cycles without any degradation of performance.

Similar Private Companies By Industry

Company Name Region
Valencia Technologies Corp United States
Cannabics Inc. United States
UVP, LLC United States
Soluble Therapeutics, LLC United States
Sofie Biosciences, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SeraCare Life Sciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at